Skip to main content

Table 2 Combined efficacy results according to primary and secondary outcomes.

From: Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

Outcomes

Pts (RCTs)

HR/RR (95% CI)

p-value

Het. (p)

AD (%)

NNT

PFS

2,624 (4)

0.62 (0.48, 0.69)

< 0.0001

0.001

17.1

6

OS

2,624 (4)

0.78 (0.66, 0.94)

0.007

0.14

8.6

12

ORR

2,728 (5)

1.16 (0.97, 1.38)

0.085

0.034

-

-

PR

1,336 (4)

1.24 (1.06, 1.46)

0.006

0.19

6.5

15

  1. Pts: patients; RCTs: randomized clinical trials; HR: hazard ratio; RR: relative risk; CI: confidence intervals; Het.: heterogeneity; AD: absolute difference; NNT: number needed to treat; PFS: progression free survival; OS: overall survival; ORR: overall response rate; PR: partial response rate.